Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
28.1.2022 15:47:00 EET | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177Lu (n.c.a. 177Lu) cutting-edge production technology LuMagic®. This agreement will enable transfer of relevant equipment and supply from Monrol to Curium.
Monrol is one of the few producers of Lutetium-177 n.c.a worldwide, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability. Curium planning to manufacture the product Lu-177 n.c.a in its Petten production facility, Netherlands. This licence is offering significant opportunities both for Curium; one of the world’s largest nuclear medicine companies and Monrol; a company which develops, manufactures, and distributes world-class radiopharmaceutical products, radioisotopes to improve quality of life of cancer patients globally.
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today and more potential treatment options in future under clinical development. Unique properties of Lutetium-177 n.c.a makes it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer.
In line with our mission to improve the quality of life of cancer patients globally, Monrol is establishing strategic partnerships with multinational pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards which will have an annual production capacity of 60 thousand doses. With its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
"Lu-177 n.c.a contributes to our mission to improve quality of life of cancer patients globally. Our new GMP certified facility exclusively designed for theranostic R&D and production with cutting edge technology will enable us to maximize supply of high-quality Lutetium. We are committed to working closely with Curium to potentially bring new therapeutic radiopharmaceutical agents into market soon to improve patients’ lives having life threatening diseases” said Monrol General Manager Aydın Kucuk”.
John Sylvester CEO of Curium’s SPECT and International businesses commented “We are delighted with Monrol as a technology partner, after extensive benchmarking this technology gave both the highest quality product with the most efficient process, as it is already proven and ‘plug and play’ in nature the time to market will be very short”.
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials and demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com
About Curium
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005174/en/
Contact information
Eczacıbaşı Monrol
Mr. Aydın Küçük
General Manager
Email: aydin.kucuk@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Commences Commercial Operations of Phase One of Plaquemines LNG1.11.2026 17:40:00 EET | Press release
On October 31, 2026, Venture Global (NYSE: VG) commenced commercial operations of the first phase of its second LNG export project – Plaquemines LNG – and the sale of low-cost, U.S. LNG to the first phase’s long-term customers. The commercial operations date (COD) for Phase 1 of Plaquemines LNG was reached in just over 53 months from the final investment decision on the project, making it among the fastest greenfield LNG projects ever completed. “Achieving commercial operations at the first phase of our second LNG project in 53 months is a testament to our team's relentless dedication and hard work,” said Venture Global CEO Mike Sabel. “We are thrilled to hit another major milestone that enables us to continue delivering reliable, affordable American LNG to the global market. We deeply appreciate the collaboration of our regulators and supply chain partners, whose shared commitment helped us deliver this project safely and on schedule.” The first post-COD cargo from Plaquemines Phase 1
From the Chishui to the Han: "Moutai Night" Debuts in Seoul to Bridge Cultural Connections1.11.2026 14:44:00 EET | Press release
On October 25, the 2026 “Moutai Night” was held in Seoul, South Korea, under the theme “Born by the Chishui River, Fragrance Along the Han River.” Over a hundred guests from China and South Korea gathered around the Han River, sharing the distinctive appeal of Chinese baijiu, and fostering cultural exchange between the two countries through fine liquor and culture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101047521/en/ The event featured an exhibition on Moutai’s brewing techniques and brand history. Hands-on experiences with Miao batik and silverwork showcased Guizhou culture, while creative cocktails brought Chinese spirits into dialogue with Korean tastes. A city-themed video, dance performances and a violin performance rounded out the program, as guests exchanged views on liquor culture in a warm atmosphere. As a flagship cultural initiative designed for global audiences, “Moutai Night” made its Seoul debut, fol
Vedanta Aluminium’s Q2FY27: Profit doubles to INR 6,187 Cr, EBITDA rises 83% YoY31.10.2026 15:12:00 EET | Press release
Vedanta Aluminium Metal Limited (BSE: 544780 & NSE: VAML), India’s largest aluminium producer, announced its unaudited financial results for the quarter and half year ended 30 September 2026, delivering solid financial and operational performance. Revenue increased to INR 22,066 crore, up 41% YoY, supported by higher volumes and improved marketing mix. EBITDA stood at INR 10,192 crore, up 83% YoY, with an EBITDA margin of ~46%. Profit after tax stood at INR 6,187 crore, more than doubling YoY with an increase of 105%. VAML strengthened its balance sheet during the quarter, reducing net debt by INR 3,090 crore QoQ, with Net Debt/EBITDA improving to 0.7x from 0.9x in Q1FY27. The company’s credit profile was validated with India Ratings upgrading its credit rating to AA+ (Stable), alongside rating reaffirmations from ICRA and CRISIL. Operationally, VAML achieved its highest-ever quarterly aluminium production of 649 KT, up 3% QoQ and 5% YoY. Value-added production reached a record 432 KT,
United States Signs Participation Contract for Expo 2030 Riyadh, Strengthening Momentum For Global Participation31.10.2026 10:38:00 EET | Press release
The United States of America has signed its Participation Contract for Expo 2030 Riyadh, marking a significant milestone in the World Expo’s preparations and further strengthening the momentum for international participation in the global event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261031669001/en/ The Participation Contract was signed by His Highness Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and U.S. Secretary of State Marco Rubio, during a bilateral meeting held on the sidelines of the 2026 G20 Foreign Ministers’ Meeting in Atlanta, Georgia. The signing marks an important step in the United States’ journey towards Expo 2030 Riyadh, paving the way for the development of its pavilion, programming and visitor experience. It also reinforces the growing international commitment to Expo 2030 Riyadh, as countries move from confirming their participation to actively sha
ADNEC Group Kickstarts November with Two of the World’s Largest Events in the Energy and Tourism Sectors31.10.2026 05:53:00 EET | Press release
ADNEC Group, a Modon company, begins November by hosting two of the world’s most significant international events in the same week. ADIPEC 2026, the world’s largest energy event, takes place at ADNEC Centre Abu Dhabi from 2 to 5 November. Meanwhile, World Travel Market (WTM) London, one of the global travel industry’s leading gatherings, takes place at the Group’s Excel London venue from 3 to 5 November. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261030918463/en/ ADNEC Centre Abu Dhabi (Photo: AETOSWire) The two events, held simultaneously at the Group’s largest venues in the UAE and the UK, reflect ADNEC Group’s capability to deliver large-scale international events across multiple markets. ADIPEC has grown alongside the venue since it was first held at the ADNEC Centre Abu Dhabi in 2006. This year’s edition is set to be the largest in the event’s history, occupying the venue’s entire 153,000 square metres of exhibition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom